According to the American College of Allergy Asthma and Immunology, nearly one in three U.S. adults report having a seasonal ...

Calcium transport into and out of mitochondria -- the powerhouses of cells -- is central to cellular energy production and cell death. To maintain the balance of calcium within these powerhouses, ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

The following is a summary of “Prevalence of Mast Cell Activation Disorders and Hereditary Alpha Tryptasemia Amongst POTS and ...

Skin microbes do more than coexist—they shape immune responses, repair tissue, and influence gene expression across your ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high valuation and future drug risks.

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...

Currently, many unmet needs exist with respect to tryptase use in clinical practice for those with such mast-cell driven disorders as systemic mastocytosis (SM). Researchers sought to present the ...

The study in the European Respiratory Journal used advanced spatial mapping techniques to compare healthy lung tissues and tissues from patients with fatal IPF. The researchers discovered that disease ...

According to results from a study published in Clinical and Experimental Allergy, systemic mastocytosis (SM) and other clonal mast cell disorders (cMCDs) were characterized by aberrant mast cell ...